Publications

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis →

Pavlick, AC, Zhao, R, Lee, C-H, Ritchings, C, Rao, S

October 2020

Manuscript

Future Oncology

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma →

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

October 2020

Manuscript

OncoImmunology

Organ dysfunction in advanced melanoma patients treated with immune checkpoint inhibitors →

Spillane, S, Baxi, SS, Torres, AZ, Lenis, D, Freedman, AN, Mariotto, A

July 2020

Manuscript

The Oncologist

Flatiron-authored

Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies →

Baron, K, Moser, JC, Patel, P, Grossman, KF, Colonna, SV, Hyngstrom, JR

May 2020

Manuscript

Journal of Oncology Pharmacy Practice

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice →

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

May 2020

Abstract

AACR Annual Meeting

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

Abstract

AACR Annual Meeting

Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma →

Whitman, ED, Scherrer, E, Ou, W, Krepler, C

May 2020

Manuscript

Future Oncology

The adoption of immune checkpoint inhibitors and patterns of care at the end of life →

Riaz, F, Gan, G, Li, F, Davidoff, AJ, Adelson, KB, Presley, CJ, Adamson, BJS, Shaw, P, Parikh, RB, Mamtani, R, Gross, CP

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy →

Hernandez-Aya, LF, Burke, M, Collins, JM, Earle, D, Hamilton, M, Nordstrom, BL, Zhang, Y, Srivastava, S

May 2020

Abstract

ASCO Annual Meeting

Real-world patterns of molecular testing in advanced melanoma: adherence to guidelines →

Olszanski, AJ, Farma, JM

May 2020

Abstract

ASCO Annual Meeting

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma →

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

January 2020

Manuscript

Acta Oncologia

Prognostic significance of cancer patient reported outcomes in cancer →

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

December 2019

Abstract

ESMO Immuno-Oncology Congress

Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with frontline BRAF/MEK inhibitors, anti-PD-1, or nivolumab/ipilimumab →

Moser, JC, Chen, D, Hu-Lieskoven, S, Grossman, KF, Patel, SB, Colonna, SV, Ying, J, Hyngstrom, JR

November 2019

Manuscript

Cancer Medicine

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma →

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

October 2019

Abstract

ESMO Annual Congress

Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies →

Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Real-world experience with pembrolizumab in patients with advanced melanoma →

Liu FX, Ou W, Diede SJ, Whitman ED

July 2019

Manuscript

Medicine

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors →

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health records study →

Sadetsky N, Chuo C-Y, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy →

Ou W, Taymor E, Diede SJ, Whitman ED

June 2019

Abstract

ASCO Annual Meeting

Impact of antibiotics on overall survival in patients with advanced non-small-cell lung cancer and melanoma treated with first-line immune checkpoint inhibition →

Bagley SJ, Dhopeshwarkar N, Narayan V, Meropol NJ, Mamtani R, Boursi B.

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records →

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Cost-Effectiveness of Multi-Gene Panel Sequencing for Patients with Advanced Melanoma →

Steuten L, Goulart B, Meropol N, Pritchard D, Ramsey S

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Treatment Sequencing and Survival Outcomes in BRAF Mutation–Positive Metastatic Melanoma Patients Treated With Immunotherapy in Routine Clinical Practices in the United States →

Sadetsky N, Chuo J, McKenna E, Troutman S, Colburn D, Atkins MB

October 2018

Abstract

Society of Melanoma Research

Adjuvant Therapy is Associated with Improved Overall Survival in Advanced Melanoma Patients in the United States →

Gu T, Le T, Moshyk A, Gooden K, Kotapati S

October 2018

Abstract

Society of Melanoma Research

Real-World (RW) Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma (MEL): Subgroup Analysis of a Retrospective Cohort Study →

Freeman M, Gupte-Singh K, You M, Le TK, Ritchings C, Rao S, Jang S

October 2018

Abstract

Society of Melanoma Research

Assessment of Real-World Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma: A Retrospective Cohort Study →

Freeman M

October 2018

Abstract

ESMO Annual Congress

Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study →

Liu F

October 2018

Abstract

ESMO Annual Congress

Treatment Patterns and Outcomes for Patients with Advanced Melanoma in US Oncology Clinical Practices →

Whitman E, Liu F, Cao X, Diede SJ, Haiderali A, Abernethy AP

September 2018

Manuscript

Future Medicine

Flatiron-authored

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Nussbaum N, Ahern E, Dougall WC, Smyth MJ

September 2018

Manuscript

OncoImmunology

Flatiron-authored

Disparities in the use of programmed death 1 immune checkpoint inhibitors →

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Immune Checkpoint Inhibitor (ICI) Treatment in Advanced Melanoma (aMel) Patients (pts) with Renal or Hepatic Dysfunction (dysf): Real-World Patient Characteristics and Outcomes →

Spillane S, Abernethy AP, Brown NR, Freedman AN, Lenis D, Maignan K, Mariotto A, Miksad RA, Torres AZ, Sharon E

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Ahern E, Dougall WC, Smyth MJ

June 2018

Abstract

ASCO Annual Meeting

Emergent Renal and Hepatic Dysfunction (dys) in a Real-World Cohort of Advanced Melanoma (aMel) Patients (pts) Receiving First Line (1L) Immune Checkpoint Inhibitors (ICIs) →

Spillane S, Abernethy AP, Brown NR, Freedman AN, Lenis D, Maignan K, Mariotto A, Miksad RA, Torres AZ, Sharon E

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive →

Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials →

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients →

Ghate S, Tang J, Li Z, Nakasato AR

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden →

Ghate S, Tang J, Li Z, Nakasato AR

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation →

Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J

June 2017

Abstract

ASCO Annual Meeting

Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma →

Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J

June 2017

Abstract

ASCO Annual Meeting

Treatment Patterns for Metastatic Melanoma in US Community Oncology Clinical Practice: A Retrospective Observational Study →

Whitman E, Liu F, Cao X, Haiderali A, Abernethy AP

June 2016

Abstract

ASCO Annual Meeting

Flatiron-authored

BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma →

Abernethy AP, Fung C, Richardson P, Eisenberg D, Connolly D, Terry M, Feinstein RN, Tucker M, Miller C, Nicacio L

June 2015

Abstract

ASCO Annual Meeting

Flatiron-authored